臨床泌尿器科76巻13号

2022年12月発行

特集 これだけは知っておきたい! 泌尿器科診療でも活きる腎臓内科の必須知識

〈腎疾患とがん診療〉

抗がん剤と腎②　免疫チェックポイント阻害薬（CPI）に伴う腎障害

著者： 田部井彬史¹ 廣村桂樹¹

所属機関： ¹群馬大学大学院医学系研究科腎臓・リウマチ内科学

ページ範囲：P.992 - P.997

文献概要

▶ポイント

・近年のがん診療の分野において免疫チェックポイント阻害薬（CPI）は重要な役割をもち始めている．

・一方でこれまでの抗がん剤治療にはみられなかった免疫有害事象のため，その治療中断を余儀なくされる場合がある．

・腎臓関連の免疫有害事象も例外ではなく，腎臓内科医と腫瘍専門医が連携を取り，早急な対応が求められる．

参考文献

1） Kane LP, et al : Signal Transduction by the TCR for Antigen. Curr Opin Immunol 12 : 242-249, 2000

2） Bour-Jordan H, et al : Intrinsic and Extrinsic Control of Peripheral T-Cell Tolerance by Costimulatory Molecules of the CD28/B7 Family. Immunol Rev 241 : 180-205, 2011

3） Schadendorf D, et al : Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 33 : 1889-1894, 2015

4） Sharpe AH, et al : The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nat Immunol 8 : 239-245, 2007

5） Cortazar FB, et al : Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI : A Multicenter Study. J Am Soc Nephrol 31 : 435-446, 2020

6） Abdel-Wahab N, et al : Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer : A Systematic Review of Case Reports. PLoS One 11 : e0160221, 2016

7） Manohar S, et al : Programmed Cell Death Protein 1 Inhibitor Treatment Is Associated with Acute Kidney Injury and Hypocalcemia : Meta-Analysis. Nephrol Dial Transplant 34 : 108-117, 2019

8） Manohar S, et al : Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy : Single Center Experience of Management and Drug Rechallenge. Kidney360 1 : 16-24, 2020

9） Vandiver JW, et al : Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab. Target Oncol 11 : 553-556, 2016

10） Shirali AC, et al : Association of Acute Interstitial Nephritis with Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. Am J Kidney Dis 68 : 287-291, 2016

11） Tabei A, et al : The Analysis of Renal Infiltrating Cells in Acute Tubulointerstitial Nephritis Induced by Anti-PD-1 Antibodies : A Case Report and Review of the Literature. Intern Med 57 : 3135-3139, 2018

12） Seethapathy H, et al : Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney Int Rep 5 : 1700-1705, 2020

13） Shimamura Y, et al : Incidence and Risk Factors of Acute Kidney Injury, and Its Effect on Mortality Among Japanese Patients Receiving Immune Check Point Inhibitors : A Single-Center Observational Study. Clin Exp Nephrol 25 : 479-487, 2021

14） Cortazar FB, et al : Clinicopathological Features of Acute Kidney Injury Associated with Immune Checkpoint Inhibitors. Kidney Int 90 : 638-647, 2016

15） Koks MS, et al : Immune Checkpoint Inhibitor-Associated Acute Kidney Injury and Mortality : An Observational Study. PLoS One 16 : e0252978, 2021

16） Gupta, S, et al : Acute Kidney Injury in Patients Treated with Immune Checkpoint Inhibitors. J Immunother Cancer 9 : e003467, 2021

17） García-Carro C, et al : Acute Kidney Injury as a Risk Factor for Mortality in Oncological Patients Receiving Checkpoint Inhibitors. Nephrol Dial Transplant 37 : 887-894, 2022

18） Liu K, et al : Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors : A Bayesian Network Meta-Analysis. Front Oncol 11 : 662731, 2021

19） Gérard AO, et al : Immune Checkpoint Inhibitors-Induced Nephropathy : A French National Survey. Cancer Immunol Immunother 70 : 3357-3364, 2021

20） Perazella MA, et al : Immune Checkpoint Inhibitor Nephrotoxicity : What Do We Know and What Should We Do? Kidney Int 97 : 62-74, 2020

21） Fadel F, et al : Anti-CTLA4 Antibody-Induced Lupus Nephritis. N Engl J Med 361 : 211-212, 2009

22） Kitchlu A, et al : A Systematic Review of Immune Checkpoint Inhibitor-Associated Glomerular Disease. Kidney Int Rep 6 : 66-77, 2021

23） Mamlouk O, et al : Nephrotoxicity of Immune Checkpoint Inhibitors Beyond Tubulointerstitial Nephritis : Single-Center Experience. J Immunother Cancer 7 : 2, 2019

24） Schneider BJ, et al : Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy : ASCO Guideline Update. J Clin Oncol 39 : 4073-4126, 2021

25） National Cancer Institute （NCI） : Common Terminology Criteria for Adverse Effects （CTCAE）. 2017　http://www.jcog.jp/doctor/tool/ctcaev5.html （2022年10月1日閲覧）

26） Rashidi A, et al : The Role of Kidney Biopsy in Immune Checkpoint Inhibitor-Associated AKI. Kidney360 3 : 530-533, 2022

27） Brahmer JR, et al : Phase I Study of Single-Agent Anti-Programmed Death-1 （MDX-1106） in Refractory Solid Tumors : Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. J Clin Oncol 28 : 3167-3175, 2010

28） Krishnan N, et al : Drug-Induced Acute Interstitial Nephritis : Pathology, Pathogenesis, and Treatment. Iran J Kidney Dis 9 : 3-13, 2015

29） Meraz-Muñoz A, et al : Acute Kidney Injury Associated with Immune Checkpoint Inhibitor Therapy : Incidence, Risk Factors and Outcomes. J Immunother Cancer 8 : e000467, 2020